Jenny Goudemand
Haematology Department
Lille University Hospital
Lille
France
Name/email consistency: high
- Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates. Goudemand, J. Haemophilia (2007)
- Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Goudemand, J., Rothschild, C., Demiguel, V., Vinciguerrat, C., Lambert, T., Chambost, H., Borel-Derlon, A., Claeyssens, S., Laurian, Y., Calvez, T. Blood (2006)
- Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. Goudemand, J., Scharrer, I., Berntorp, E., Lee, C.A., Borel-Derlon, A., Stieltjes, N., Caron, C., Scherrmann, J.M., Bridey, F., Tellier, Z., Federici, A.B., Mannucci, P.M. J. Thromb. Haemost. (2005)
- Cases of surgery in high-responder haemophilia patients. Goudemand, J., Tagariello, G., Lopaciuk, F. Haemophilia (2004)
- Standardization of factor VII/activated factor VII measurement in plasma of patients treated with recombinant factor activated VII. Goudemand, J., Caron, C., Dreyfus, M., Sié, P. Blood Coagul. Fibrinolysis (2003)
- Clinical management of patients with von Willebrand's disease with a VHP vWF concentrate: the French experience. Goudemand, J., Negrier, C., Ounnoughene, N., Sultan, Y. Haemophilia (1998)
